Axway Recognized as a Strong Performer in Independent Report on Strategic iPaaS And Hybrid Integration Platforms
Axway (Paris:AXW) (Euronext: AXW.PA) the leader in cloud enabled integration, announced today it has been positioned as a Strong Performer in The Forrester Wave™: Strategic iPaaS And Hybrid Integration Platforms, Q1 2019. In the report, Forrester evaluated the Axway AMPLIFY platform and explains that “Axway provides an integrated platform for no-code/low-code app development, API creation and management, and MFT-, EDI-, and API-led B2B integration.”¹
According to the report, “The strategic iPaaS/HIP market is growing because more EA professionals see strategic iPaaS/HIP as a key element of their digital transformation agility.”¹
“At Axway we believe that integration must transform to address the IT challenges of delivering business outcomes,” said Vince Padua, Axway’s Chief Information and Technology Officer. “As we continue to help our customers and partners, we are pleased to be recognized as a strong performer in The Forrester Wave™: Strategic iPaaS And Hybrid Integration Platforms. We think this distinction underscores our integration strengths across API, MFT, B2Bi, EDI, Content Collaboration, multi-cloud, and multi-persona.”
The report further describes the AMPLIFY platform - Axway’s enterprise-ready hybrid integration platform - in saying, “All of these capabilities benefit from integrated operational intelligence, partner onboarding, plus a portal enabling companies to build ecosystems centrally, delivering the best customer experiences to the end customers.”¹
This announcement comes shortly after The Forrester Wave™: API Management Solutions Q4 2018 also recognized Axway as a Strong Performer, saying, “Overall, the reference customers provided by Axway are extremely satisfied with the vendor and highly satisfied with its solution…”²
Today’s report affirms, in our opinion, Axway’s position with its customers, indicating that customers appreciate the relationship they have with Axway.
Axway plans to roll out the next major release of the AMPLIFY platform at its IMAGINE SUMMIT customer events in Orlando and Paris in March.
“Aligned with our upcoming product and platform announcements, we will continue to pursue reducing the time and cost of integration through a unified platform, such that businesses and application leaders can better address the integration challenges brought by digital transformation,” said Padua.
For more information about Hybrid Integration, visit the Axway HIP Resource Center.
Click here to read the full report (client access or for purchase).
¹ The Forrester Wave™: Strategic iPaaS And Hybrid Integration Platforms, Q1 2019, Forrester Research, Inc., January 3, 2019
Axway (Euronext: AXW.PA) is a catalyst for transformation. With Axway AMPLIFY™, our cloud-enabled integration and engagement platform, digital leaders anticipate, adapt and scale to meet rising customer expectations. Our unified, API-first approach connects data from anywhere, expands collaboration, fuels millions of apps and delivers real-time analytics to build customer experience networks. From idea to execution, we help make the future possible for more than 11,000 organizations in 100 countries. To learn more, visit www.axway.com.
Tel. (480) 627-1891
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Knopp Biosciences Announces Start of Phase 2 Clinical Trial Evaluating Oral Dexpramipexole in Moderate-to-Severe Eosinophilic Asthma19.8.2019 10:00:00 CEST | Press release
Knopp Biosciences LLC today announced the start of Phase 2 dose-ranging clinical trial in moderate-to-severe eosinophilic asthma. Recruitment in the trial is underway and the first patient has been enrolled. The Company anticipates reporting top-line data from this trial in the second half of 2020. This 12-week biomarker study is planned to randomize approximately 100 patients with eosinophilic asthma to investigate the eosinophil response to three different doses of oral dexpramipexole. The primary outcome measure of this randomized, double-blind, placebo-controlled study is the change in blood absolute eosinophil count from Baseline to Week 12. The secondary outcome measures include changes in pre-bronchodilator FEV1 and asthma control outcomes (ACQ-7 questionnaire) from baseline to week 12. “We estimate that there are more than two million moderate-to-severe eosinophilic asthma patients in the U.S. and are excited about further characterizing the clinical profile of oral dexpramipex
CES Unveiled in Amsterdam to Showcase Tech for Good19.8.2019 07:00:00 CEST | Press release
Consumer Technology Association (CTA): WHAT: The Consumer Technology Association (CTA)® today announced several government officials, dignitaries and industry leaders attending CES Unveiled in Amsterdam, an official CES preview event, focusing on the theme “Tech for Good.” Returning for its third year, CES Unveiled in Amsterdam will bring together executives, influential media, prominent industry influencers, and more than 100 companies (including 50+ startups) to explore the latest technology trends and innovations from the Netherlands and surrounding European countries leading up to CES® 2020. Attendees and media are able to register for CES Unveiled in Amsterdam online. WHO: Government officials and dignitaries including Mona Keijzer, Netherlands State Secretary for Economic Affairs and Climate Policy; HRH Prince Constantijn van Oranje, Special Envoy at TechLeap.NL; and Pete Hoekstra, U.S. Ambassador to the Netherlands, will share insights on emerging trends in the industry, includi
RISO Unveils VALEZUS, a New Brand for the Production-printing Market19.8.2019 06:00:00 CEST | Press release
RISO KAGAKU CORPORATION (President & CEO: Akira Hayama; hereinafter “RISO”) announced today the launch of VALEZUS, a new brand of high-speed ink-jet printers for the production-printing market. RISO will start with successive rollouts worldwide of the new brand’s first product, the VALEZUS T2100, a high-speed, 320-page-per-minute (320-ppm) cut-sheet printer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190818005001/en/ 1 The new brand, VALEZUS One of RISO’s commanding strengths is the development of inks optimized for high-speed paper feeding and high-speed printing. This expertise enables RISO to deliver unique printing solutions serving the demand for high-volume printing. With technologies developed and cultivated in this field, RISO launches the VALEZUS, a fresh brand targeting the production-printing market. 2 The all-new VALEZUS T2100 VALEZUS T2100 The first product of the new brand, the VALEZUS T2100 is a high-speed
Velodyne Files Patent Infringement Complaint with ITC Against Hesai and RoboSense16.8.2019 12:00:00 CEST | Press release
Velodyne Lidar, Inc. filed a patent infringement complaint with the U.S. International Trade Commission (ITC) against Hesai Photonics Technology Co., Ltd. and Suteng Innovation Technology Co., Ltd. (a.k.a. RoboSense) for violations of section 337 of the Tariff Act of 1930 which makes unfair methods of competition and importation of certain products into the United States unlawful. Earlier this week, Velodyne also filed patent infringement complaints against Hesai and RoboSense in the U.S. District Court for the Northern District of California. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190816005041/en/ Velodyne Lidar’s Alpha Puck™, Ultra Puck™ and Puck™ surround view sensors (left to right). (Photo: Business Wire) Velodyne is asking the ITC to investigate these lidar manufacturers for unlawfully importing and selling lidar sensors that infringe Velodyne’s patented lidar technology (U.S. Patent 7,969,558). Velodyne reques
Merz Announces Key Governance Changes16.8.2019 09:26:00 CEST | Press release
Merz, a global leader in medical aesthetics and specialty neurology, announced today that Philip Burchard will be appointed Chairman of the company’s Shareholders Council. He will assume this role in addition to his current position as Chief Executive Officer of the Merz Healthcare Group. In his new position, Philip Burchard will succeed Andreas Krebs, who has decided to step down from his current roles as Chairman of the Shareholders Council and Supervisory Board of Merz in order to dedicate more time to his personal entrepreneurial and philanthropic activities. In addition, Dr. Christian Holzherr will be the new Chairman of the Merz Supervisory Board. All changes will be effective as of October 31, 2019. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190816005106/en/ Philip Burchard, CEO of Merz (Photo: Business Wire) Philip Burchard joined Merz as CEO in July 2012. Under his leadership, Merz has focused its strategy on ae
FINEOS lists on the Australian Securities Exchange16.8.2019 07:22:00 CEST | Press release
FINEOS Corporation Holdings plc (ASX:FCL), a leading provider of group and individual core systems for life, accident and health insurance, today announced the commencement of trading on the Australian Securities Exchange (ASX) via an initial public offering (IPO). The total number of securities (CHESS Depository Interests or “CDIs”) on offer was 84.4 million at a price of A$2.50 per CDI. Total gross proceeds from the offer amounted to A$211 million. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190816005058/en/ FINEOS lists on the Australian Securities Exchange (Photo: Business Wire) FINEOS intends to use the net proceeds from the IPO to invest further in R&D to grow the FINEOS product footprint and develop new business lines, to invest in additional sales, marketing and client account management capabilities and to pay down existing debt and shareholders selling down. Key areas of growth strategy for FINEOS include: • Inc